Pramipexole — a new dopamine agonist for the treatment of Parkinson's disease
- 1 February 1999
- journal article
- review article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 163 (1) , 25-31
- https://doi.org/10.1016/s0022-510x(98)00307-4
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesionsAnnals of Neurology, 1998
- Pharmacological approaches to counter the toxicity of dopaAmino Acids, 1998
- Antidepressant effects of pramipexole, a novel dopamine receptor agonistJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1997
- Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexoleJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1997
- Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopaAnnals of Neurology, 1996
- Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptorsEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Molecular Diversity of the Dopamine ReceptorsAnnual Review of Pharmacology and Toxicology, 1993
- Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1993
- The neostriatal mosaic: multiple levels of compartmental organizationTrends in Neurosciences, 1992
- Dopamine Auto- and Postsynaptic Receptors: Electrophysiological Evidence for Differential Sensitivity to Dopamine AgonistsScience, 1979